A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of SCH 530348 in addition to standard of care in subjects with a history of atherosclerotic disease: Thrombin Receptor Antagonist in secondary Prevention of Atherothrombotic Ischemic Events (TRA 2P - TIMI 50).

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of SCH 530348 in addition to standard of care in subjects with a history of atherosclerotic disease: Thrombin Receptor Antagonist in secondary Prevention of Atherothrombotic Ischemic Events (TRA 2P - TIMI 50).

Completed
Phase of Trial: Phase III

Latest Information Update: 07 May 2017

At a glance

  • Drugs Vorapaxar (Primary)
  • Indications Atherosclerosis; Cardiovascular disorders; Cerebrovascular disorders; Ischaemia; Myocardial infarction; Peripheral arterial disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms TRA-2P; TRA2degP-TIMI50; TRA2P-TIMI 50
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 20 Jul 2016 Results (n=8598) assessing clinical indicators atherothrombotic risk published in the Circulation
    • 29 Jan 2016 Results published in the Circulation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top